Anti-human PVRIG antibody and application thereof
By developing antibodies that can bind PVRIG with high affinity and inhibiting its binding activity with PVRL2, the problem of high expression and adverse prognosis of PVRIG in tumor tissues is solved, and the effect of enhancing T cell activation and inhibiting tumor growth is achieved.
CN120025447APending Publication Date: 2025-05-23GUANGDONG FAPON BIOPHARMA INC +1
8 Cites 1 Cited by
Patent Information
- Application Number
- CN202411681080.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-11-23
- Filing Date
- 2024-11-21
- Publication Date
- 2025-05-23
AI Technical Summary
Technical Problem
The prior art is difficult to effectively solve the problems of high expression and adverse prognosis of PVRIG in tumor tissues, especially during T cell activation and depletion.
Method used
An anti-human PVRIG antibody is developed that contains specific heavy and light chain variable regions capable of binding PVRIG with high affinity and inhibiting its binding activity to PVRL2.
Benefits of technology
By inhibiting the binding of PVRIG to PVRL2, antibodies can enhance T cell activation and function, thereby potentially inhibiting tumor growth and progression.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention relates to the technical field of biology, and discloses an anti-human PVRIG antibody and application thereof. The anti-human PVRIG antibody disclosed by the invention is specifically combined with a human PVRIG antigen and can be used for tumor treatment.
Need to check novelty before this filing date? Find Prior Art